{"id":"W3184904659","doi":"10.1158/0008-5472.can-21-0774","title":"Acquired <i>RAD51C</i> Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Institute of General Medical Sciences; Cancer Council Tasmania; Cancer Council Victoria; Cancer Council South Australia; Victorian Cancer Agency; Entertainment Industry Foundation; Stand Up To Cancer; Medical Research Council; Peter MacCallum Foundation; AstraZeneca Australia; Medical Research and Materiel Command; Eisai; Ovarian Cancer Research Fund; Cancer Australia; National Cancer Institute; Australian Cancer Research Foundation; Mayo Foundation for Medical Education and Research; State Government of Victoria; Australian Government; Cancer Council NSW; Ovarian Cancer Australia; National Breast Cancer Foundation; Clovis Oncology; Sierra Oncology; National Ovarian Cancer Coalition; American Association for Cancer Research; National Health and Medical Research Council; Cancer Research Institute; AstraZeneca; Ovarian Cancer Research Fund Alliance; National Institutes of Health","keywords":"Serous fluid; PARP inhibitor; Ovarian carcinoma; Methylation; Cancer research; Medicine; Ovarian cancer; Oncology; Internal medicine; Biology; Poly ADP ribose polymerase; Cancer; Gene; Genetics; Polymerase","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001106779,0.0002548507,0.0005084376,0.0003902709,0.0002028924,0.00009215384,0.0002083945,0.0002418644,0.0008556135],"category_scores_gemma":[0.0002411217,0.0002550937,0.00009948566,0.001911977,0.0003362561,0.0002558333,0.0001168278,0.0006911419,0.00006959417],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001615956,"about_ca_system_score_gemma":0.001770978,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009868202,"about_ca_topic_score_gemma":0.003021948,"domain_scores_codex":[0.9956889,0.0006803354,0.0005502816,0.0008629998,0.001313135,0.0009043979],"domain_scores_gemma":[0.997651,0.0002534759,0.00009643476,0.0008524745,0.0008465987,0.0003000236],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.002371279,0.000587249,0.05854839,0.0008599305,0.0001463013,0.002440632,0.003197327,0.00003531078,0.9085491,0.002119653,0.01914155,0.002003278],"study_design_scores_gemma":[0.007252018,0.0001912201,0.08660529,0.001017923,0.00003145844,0.00005981634,0.0003059607,0.00002084779,0.8572535,0.003557888,0.04332886,0.000375245],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9701827,0.007583152,0.00007068926,0.01924831,0.0005039541,0.0009646059,0.00009059058,0.00008546796,0.001270548],"genre_scores_gemma":[0.9902145,0.0009255889,0.0008723296,0.0007624761,0.001108404,0.000805151,0.00009037954,0.0000848488,0.005136378],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05129563,"threshold_uncertainty_score":0.9999901,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09252431265740614,"score_gpt":0.4020122372412097,"score_spread":0.3094879245838036,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}